Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.50 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 8/20 | 0.45 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26239722 | 0.94 | ALDH1A1 (0.53) | CYP4F2CYP4A11ALDH1A1GAAGFER | |
| SCHEMBL26239742 | 0.94 | ALDH1A1 (0.53) | CYP4F2CYP4A11ALDH1A1GAAGFER | |
| SCHEMBL14420145 | 0.88 | CYP4F2 (0.47) | CYP4F2CYP4A11ALDH1A1GAAGFER | |
| SCHEMBL14420105 | 0.87 | CYP4F2 (0.46) | CYP4F2CYP4A11ALDH1A1GAAGFER | |
| SCHEMBL12508636 | 0.86 | CYP4F2 (0.51) | CYP4F2CYP4A11ALDH1A1GAAGFER | |
| SCHEMBL14420065 | 0.84 | CYP4F2 (0.44) | CYP4F2CYP4A11ALDH1A1GAAGFER | |
| SCHEMBL14301862 | 0.83 | ALDH1A1 (0.57) | CYP4F2CYP4A11ALDH1A1GAAGFER | |
| SCHEMBL26240068 | 0.82 | CYP4F2 (0.45) | CYP4F2CYP4A11ALDH1A1MEN1KMT2A | |
| SCHEMBL26239774 | 0.82 | MEN1 (0.50) | ALDH1A1MEN1KMT2A | |
| SCHEMBL27473665 | 0.82 | CYP4F2 (0.68) | CYP4F2CYP4A11ALDH1A1GAAGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024098361-A1 | ARTIFICIAL NUCLEIC ACID MOLECULE | 斯微(上海)生物科技股份有限公司 | 2024-05-16 | — | — | WO | disclosed |
| US-20230263742-A1 | A LIPID | Stemirna Therapeutics Co., Ltd. (CN) | 2023-08-24 | — | — | US | disclosed |
| US-20230263742-A1 | A LIPID | Stemirna Therapeutics Co., Ltd. (CN) | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230263742-A1 | A LIPID | CETP, PLIN1, AUP1 | CYP4F2 1444/4885CYP4A11 2063/4885ALDH1A1 1643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.